FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282983705> ?p ?o ?g. }

• W4282983705 endingPage "3959" @default.
• W4282983705 startingPage "3959" @default.
• W4282983705 abstract "Abstract Introduction: BCL2 family protein dysfunction is an important mediator of chemoresistance in lymphoid malignancies. Venetoclax (VEN), a BH3 mimetic that selectively targets the anti-apoptotic protein BCL2, is FDA approved for treatment of chronic lymphocytic leukemia (CLL), with clinical trials underway for other lymphoid malignancies. Despite the clinical efficacy of VEN monotherapy, complete remission and progression free rates are still relatively low, thereby indicating the existence of inherent or acquired mechanisms of resistance. Preclinically, increases in anti-apoptotic BCL2 and MCL1 phosphorylation (BCL2-P/MCL1-P) and MCL1 protein level have been implicated in chemoresistance. We therefore question if phosphorylation of these proteins may drive VEN resistance and if removing this modification may re-sensitize resistant cells to VEN induced cell death. Methodology: BH3 profiling (a functional assay that assesses mitochondrial apoptotic priming and anti-apoptotic protein dependence), western blot and cell death assays were performed. Result: We report that VEN acquired resistant DLBCL cell line (OCI-Ly1R) has increased BCL2-P, MCL1-P and MCL1 protein levels as compared to sensitive parental cell line (OCI-Ly1S), while inherently resistant DHL cell line (Su-DHL4) possesses higher MCL1-P and MCL1 protein levels as compared to OCI-Ly1S. We further show that this increase in phosphorylation status contributes to the induction of VEN resistance. Using BH3 profiling, we demonstrate that anti-apoptotic protein phosphorylation-driven VEN resistance involves a change in sensitivity to pro-apoptotic proteins, with an increase in sensitivity to MCL1 inhibition and reciprocal decrease in sensitivity to BCL2 inhibition. We further show that BCL2 and MCL1 dephosphorylation by PP2A activating drugs (PADs) re-sensitizes resistant cells to VEN treatment. Mechanistically, PADs such as the fingolimod (FTY720) not only dephosphorylate BCL2-P and MCL1-P, but also dissociate BAX from BCL2 and destabilize MCL1 protein. These changes lead to the rewiring of cellular sensitivity to BCL2 inhibition, thereby re-sensitizing both VEN acquired and inherent resistant cells to VEN induced cell death. Importantly, the PP2A activating effects of FTY720 were recapitulated in primary cells from the peripheral blood of 16 CLL patients, where FTY720 treatment also reduced BCL2-P, MCL1-P and MCL1 protein levels and dissociated BAX from BCL2. This led to an increased sensitivity to BCL2 inhibition and enhanced cell death upon combined treatment with FTY720 and VEN. Conclusion: Our work defines a new targetable mechanism of VEN resistance in lymphoid malignancies due to the phosphorylation of anti-apoptotic BCL2 family proteins. PADs re-sensitize resistant malignant cells to VEN treatment via dephosphorylation of anti-apoptotic proteins, suggesting a promising combination approach to explore further. Citation Format: Stephen J. Chong, Fen Zhu, Jolin X. Lai, Liam Hackett, Mary C. Collins, Shazib Pervaiz, Jean-Philippe Coppe, Matthew S. Davids. Targeting BCL2 family protein phosphorylation in venetoclax resistant lymphoid malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3959." @default.
• W4282983705 created "2022-06-17" @default.
• W4282983705 creator A5018834596 @default.
• W4282983705 creator A5021625294 @default.
• W4282983705 creator A5038876039 @default.
• W4282983705 creator A5047387130 @default.
• W4282983705 creator A5056994035 @default.
• W4282983705 creator A5063159222 @default.
• W4282983705 creator A5063755644 @default.
• W4282983705 creator A5084717567 @default.
• W4282983705 date "2022-06-15" @default.
• W4282983705 modified "2023-09-25" @default.
• W4282983705 title "Abstract 3959: Targeting BCL2 family protein phosphorylation in venetoclax resistant lymphoid malignancies" @default.
• W4282983705 doi "https://doi.org/10.1158/1538-7445.am2022-3959" @default.
• W4282983705 hasPublicationYear "2022" @default.
• W4282983705 type Work @default.
• W4282983705 citedByCount "1" @default.
• W4282983705 countsByYear W42829837052023 @default.
• W4282983705 crossrefType "journal-article" @default.
• W4282983705 hasAuthorship W4282983705A5018834596 @default.
• W4282983705 hasAuthorship W4282983705A5021625294 @default.
• W4282983705 hasAuthorship W4282983705A5038876039 @default.
• W4282983705 hasAuthorship W4282983705A5047387130 @default.
• W4282983705 hasAuthorship W4282983705A5056994035 @default.
• W4282983705 hasAuthorship W4282983705A5063159222 @default.
• W4282983705 hasAuthorship W4282983705A5063755644 @default.
• W4282983705 hasAuthorship W4282983705A5084717567 @default.
• W4282983705 hasConcept C104317684 @default.
• W4282983705 hasConcept C11960822 @default.
• W4282983705 hasConcept C127561419 @default.
• W4282983705 hasConcept C190283241 @default.
• W4282983705 hasConcept C203014093 @default.
• W4282983705 hasConcept C2777938653 @default.
• W4282983705 hasConcept C2778461978 @default.
• W4282983705 hasConcept C2779176958 @default.
• W4282983705 hasConcept C2779675984 @default.
• W4282983705 hasConcept C31573885 @default.
• W4282983705 hasConcept C33195913 @default.
• W4282983705 hasConcept C502942594 @default.
• W4282983705 hasConcept C54355233 @default.
• W4282983705 hasConcept C71924100 @default.
• W4282983705 hasConcept C86803240 @default.
• W4282983705 hasConcept C95444343 @default.
• W4282983705 hasConcept C98424977 @default.
• W4282983705 hasConceptScore W4282983705C104317684 @default.
• W4282983705 hasConceptScore W4282983705C11960822 @default.
• W4282983705 hasConceptScore W4282983705C127561419 @default.
• W4282983705 hasConceptScore W4282983705C190283241 @default.
• W4282983705 hasConceptScore W4282983705C203014093 @default.
• W4282983705 hasConceptScore W4282983705C2777938653 @default.
• W4282983705 hasConceptScore W4282983705C2778461978 @default.
• W4282983705 hasConceptScore W4282983705C2779176958 @default.
• W4282983705 hasConceptScore W4282983705C2779675984 @default.
• W4282983705 hasConceptScore W4282983705C31573885 @default.
• W4282983705 hasConceptScore W4282983705C33195913 @default.
• W4282983705 hasConceptScore W4282983705C502942594 @default.
• W4282983705 hasConceptScore W4282983705C54355233 @default.
• W4282983705 hasConceptScore W4282983705C71924100 @default.
• W4282983705 hasConceptScore W4282983705C86803240 @default.
• W4282983705 hasConceptScore W4282983705C95444343 @default.
• W4282983705 hasConceptScore W4282983705C98424977 @default.
• W4282983705 hasIssue "12_Supplement" @default.
• W4282983705 hasLocation W42829837051 @default.
• W4282983705 hasOpenAccess W4282983705 @default.
• W4282983705 hasPrimaryLocation W42829837051 @default.
• W4282983705 hasRelatedWork W1978770507 @default.
• W4282983705 hasRelatedWork W2000225649 @default.
• W4282983705 hasRelatedWork W2036855371 @default.
• W4282983705 hasRelatedWork W2178462734 @default.
• W4282983705 hasRelatedWork W2315878389 @default.
• W4282983705 hasRelatedWork W2581748696 @default.
• W4282983705 hasRelatedWork W2589312954 @default.
• W4282983705 hasRelatedWork W3137744829 @default.
• W4282983705 hasRelatedWork W4206614737 @default.
• W4282983705 hasRelatedWork W4282983705 @default.
• W4282983705 hasVolume "82" @default.
• W4282983705 isParatext "false" @default.
• W4282983705 isRetracted "false" @default.
• W4282983705 workType "article" @default.